

BROOKS AUTOMATION INC
Form 10-Q
April 30, 2015
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended: March 31, 2015

OR

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _____ to _____
Commission File Number 000-25434

BROOKS AUTOMATION, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
15 Elizabeth Drive
Chelmsford, Massachusetts
(Address of principal executive offices)

04-3040660
(I.R.S. Employer
Identification No.)

01824
(Zip Code)

Registrant's telephone number, including area code: (978) 262-2400

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Edgar Filing: BROOKS AUTOMATION INC - Form 10-Q

Large accelerated filer Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practical date, April 23, 2015: common stock, \$0.01 par value and 67,481,408 shares outstanding.

Table of Contents

BROOKS AUTOMATION, INC.

Table of Contents

| | PAGE NUMBER |
|--|-------------|
| <u>PART I. FINANCIAL INFORMATION</u> | <u>3</u> |
| <u>Item 1. Consolidated Financial Statements</u> | <u>3</u> |
| <u>Consolidated Balance Sheets as of March 31, 2015 and September 30, 2014 (unaudited)</u> | <u>3</u> |
| <u>Consolidated Statements of Operations for the three and six months ended March 31, 2015 and 2014 (unaudited)</u> | <u>4</u> |
| <u>Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended March 31, 2015 and 2014 (unaudited)</u> | <u>5</u> |
| <u>Consolidated Statements of Cash Flows for the six months ended March 31, 2015 and 2014 (unaudited)</u> | <u>6</u> |
| <u>Notes to Consolidated Financial Statements (unaudited)</u> | <u>7</u> |
| <u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>26</u> |
| <u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u> | <u>33</u> |
| <u>Item 4. Controls and Procedures</u> | <u>33</u> |
| <u>PART II. OTHER INFORMATION</u> | <u>33</u> |
| <u>Item 1. Legal Proceedings</u> | <u>33</u> |
| <u>Item 1A. Risk Factors</u> | <u>33</u> |
| <u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u> | <u>34</u> |
| <u>Item 6. Exhibits</u> | <u>35</u> |
| <u>Signatures</u> | <u>36</u> |

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

BROOKS AUTOMATION, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except share and per share data)

| | March 31, 2015 | September 30, 2014 |
|---|-------------------|-----------------------|
| Assets | | |
| Current assets | | |
| Cash and cash equivalents | \$73,176 | \$ 94,114 |
| Marketable securities | 69,327 | 68,130 |
| Accounts receivable, net | 94,679 | 80,106 |
| Inventories | 90,558 | 93,567 |
| Deferred tax assets | 18,871 | 19,009 |
| Prepaid expenses and other current assets | 14,841 | 19,387 |
| Total current assets | 361,452 | 374,313 |
| Property, plant and equipment, net | 46,833 | 50,183 |
| Long-term marketable securities | 64,601 | 83,212 |
| Long-term deferred tax assets | 69,595 | 67,563 |
| Goodwill | 118,264 | 109,501 |
| Intangible assets, net | 59,693 | 59,550 |
| Equity method investments | 27,027 | 28,944 |
| Other assets | 9,490 | 4,772 |
| Total assets | \$756,955 | \$ 778,038 |
| Liabilities and equity | | |
| Current liabilities | | |
| Accounts payable | \$43,610 | \$ 33,740 |
| Capital lease obligation | 881 | 881 |
| Deferred revenue | 19,943 | 26,279 |
| Accrued warranty and retrofit costs | 6,203 | 6,499 |
| Accrued compensation and benefits | 15,345 | 21,663 |
| Accrued restructuring costs | 3,297 | 3,475 |
| Accrued income taxes payable | 2,789 | 1,808 |
| Deferred tax liabilities | 458 | 808 |
| Accrued expenses and other current liabilities | 15,027 | 18,688 |
| Total current liabilities | 107,553 | 113,841 |
| Long-term capital lease obligation | 7,173 | 7,417 |
| Long-term tax reserves | 4,175 | 5,708 |
| Long-term deferred tax liabilities | 3,418 | 2,567 |
| Long-term pension liability | 2,342 | 1,774 |
| Other long-term liabilities | 3,467 | 3,842 |
| Total liabilities | 128,128 | 135,149 |
| Commitments and contingencies (Note 18) | | |
| Equity | | |
| Preferred stock, \$0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding | — | — |
| | 809 | 804 |

Edgar Filing: BROOKS AUTOMATION INC - Form 10-Q

Common stock, \$0.01 par value, 125,000,000 shares authorized, 80,943,277 shares issued and 67,481,408 shares outstanding at March 31, 2015, 80,375,777 shares issued and 66,913,908 shares outstanding at September 30, 2014

| | | |
|---|--------------|--------------|
| Additional paid-in capital | 1,840,426 | 1,834,619 |
| Accumulated other comprehensive income | 9,333 | 15,687 |
| Treasury stock at cost, 13,461,869 shares | (200,956) | (200,956) |
| Accumulated deficit | (1,020,785) | (1,007,265) |
| Total equity | 628,827 | 642,889 |
| Total liabilities and equity | \$756,955 | \$ 778,038 |

The accompanying notes are an integral part of these unaudited consolidated financial statements.

3

Table of Contents

BROOKS AUTOMATION, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except per share data)

| | Three months ended March 31, | | Six months ended March 31, | |
|--|---------------------------------|------------|-------------------------------|------------|
| | 2015 | 2014 | 2015 | 2014 |
| Revenue | | | | |
| Product | \$ 116,395 | \$ 102,534 | \$ 216,125 | \$ 195,664 |
| Services | 22,918 | 23,366 | 45,924 | 47,308 |
| Total revenue | 139,313 | 125,900 | 262,049 | 242,972 |
| Cost of revenue | | | | |
| Product | 79,048 | 64,786 | 149,268 | 125,522 |
| Services | 14,240 | 16,816 | 27,668 | 32,261 |
| Total cost of revenue | 93,288 | 81,602 | 176,936 | 157,783 |
| Gross profit | 46,025 | 44,298 | 85,113 | 85,189 |
| Operating expenses | | | | |
| Research and development | 12,678 | 12,493 | 26,167 | 25,044 |
| Selling, general and administrative | 29,609 | 28,637 | 59,020 | 54,772 |
| Restructuring and other charges | 685 | 772 | 3,353 | 1,519 |
| Total operating expenses | 42,972 | 41,902 | 88,540 | 81,335 |
| Operating income (loss) | 3,053 | 2,396 | (3,427) |) 3,854 |
| Interest income | 228 | 258 | 479 | 504 |
| Interest expense | (98) |) — | (200) |) — |
| Other income, net | 1,161 | 56 | 2,180 | 315 |
| Income (loss) before income taxes and equity in earnings (losses) of equity method investments | 4,344 | 2,710 | (968) |) 4,673 |
| Income tax provision (benefit) | 1,560 | 1,117 | (1,550) |) 1,910 |
| Income before equity in earnings (losses) of equity method investments | 2,784 | 1,593 | 582 | 2,763 |
| Equity in earnings (losses) of equity method investments | (73) |) 510 | (605) |) 1,259 |
| Income (loss) from continuing operations | 2,711 | 2,103 | (23) |) 4,022 |
| Income from discontinued operations, net of tax | — | 1,162 | — | 2,739 |
| Net income (loss) | 2,711 | 3,265 | (23) |) 6,761 |
| Net income attributable to noncontrolling interests | — | (76) |) — | (124) |
| Net income (loss) attributable to Brooks Automation, Inc. | \$ 2,711 | \$ 3,189 | \$ (23) |) \$ 6,637 |
| Basic net income (loss) per share attributable to Brooks Automation, Inc. common stockholders: | | | | |
| Net income (loss) from continuing operations | \$ 0.04 | \$ 0.03 | \$ — | \$ 0.06 |
| Net income from discontinued operations, net of tax | — | 0.02 | — | 0.04 |
| Basic net income (loss) per share attributable to Brooks Automation, Inc. | \$ 0.04 | \$ 0.05 | \$ — | \$ 0.10 |
| Diluted net income (loss) per share attributable to Brooks Automation, Inc. common stockholders: | | | | |
| Net income (loss) from continuing operations | \$ 0.04 | \$ 0.03 | \$ — | \$ 0.06 |
| Net income from discontinued operations, net of tax | — | 0.02 | — | 0.04 |

Edgar Filing: BROOKS AUTOMATION INC - Form 10-Q

| | | | | |
|--|--------|--------|--------|--------|
| Diluted net income (loss) per share attributable to Brooks Automation, Inc. | \$0.04 | \$0.05 | \$— | \$0.10 |
| Dividend declared per share | \$0.10 | \$0.08 | \$0.20 | \$0.16 |
| Shares used in computing earnings (loss) per share: | | | | |
| Basic | 67,387 | 66,646 | 67,255 | 66,499 |
| Diluted | 68,414 | 67,505 | 67,255 | 67,383 |

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

Table of Contents

BROOKS AUTOMATION, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(unaudited)
(In thousands)

| | Three months ended March 31, | | Six months ended March 31, | |
|---|---------------------------------|---------|-------------------------------|---------|
| | 2015 | 2014 | 2015 | 2014 |
| Net income (loss) | \$2,711 | \$3,265 | \$(23) | \$6,761 |
| Comprehensive income (loss): | | | | |
| Change in cumulative translation adjustment | (2,423) | (547) | (6,565) | (841) |
| Change in unrealized gain on marketable securities | 267 | 22 | 202 | 21 |
| Change in fair value on cash flow hedges | — | (37) | — | 68 |
| Actuarial gain (loss) | (13) | 10 | 9 | 21 |
| Comprehensive income (loss) | 542 | 2,713 | (6,377) | 6,030 |
| Comprehensive income attributable to noncontrolling interests | — | (76) | — | (124) |
| Comprehensive income (loss) attributable to Brooks Automation, Inc. | \$542 | \$2,637 | \$(6,377) | \$5,906 |

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BROOKS AUTOMATION, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)

| | Six months ended March 31, | |
|--|----------------------------|-----------|
| | 2015 | 2014 |
| Cash flows from operating activities | | |
| Net income (loss) | \$(23 |) \$6,761 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | | |
| Depreciation and amortization | 12,733 | 11,170 |
| Impairment of intangible assets | — | 398 |
| Stock-based compensation | 7,108 | 6,516 |
| Amortization of premium on marketable securities | 634 | 610 |
| Undistributed losses (earnings) of equity method investments | 605 | (1,259 |
| Deferred income tax provision (benefit) | (2,728 |) 2,269 |
| (Gain) loss on disposal of long-lived assets | (4 |) 39 |
| Changes in operating assets and liabilities, net of acquisitions and disposals: | | |
| Accounts receivable | (13,269 |) (6,057 |
| Inventories | 2,474 | 276 |
| Prepaid expenses and other current assets | (5,365 |) 1,546 |
| Accounts payable | 8,345 | 248 |
| Deferred revenue | (3,868 |) 13,408 |
| Accrued warranty and retrofit costs | (274 |) (951 |
| Accrued compensation and benefits | (6,200 |) 2,730 |
| Accrued restructuring costs | (6 |) 141 |
| Accrued expenses and other current liabilities | 4,791 | (2,194 |
| Net cash provided by operating activities | 4,953 | 35,651 |
| Cash flows from investing activities | | |
| Purchases of property, plant and equipment | (3,647 |) (2,696 |
| Purchases of marketable securities | (30,739 |) (63,561 |
| Sale/maturity of marketable securities | 47,625 | 46,551 |
| Acquisitions, net of cash acquired | (17,257 |) — |
| Proceeds from the sale of property, plant and equipment | 6 | — |
| Other investment | (5,000 |) (4,000 |
| Decrease in restricted cash | — | 177 |
| Net cash used in investing activities | (9,012 |) (23,529 |
| Cash flows from financing activities | | |
| Proceeds from issuance of common stock, net of issuance costs | 867 | 967 |
| Principal repayment of capital lease obligation | (244 |) — |
| Common stock dividend paid | (13,480 |) (10,800 |
| Net cash used in financing activities | (12,857 |) (9,833 |
| Effects of exchange rate changes on cash and cash equivalents | (4,022 |) 21 |
| Net increase (decrease) in cash and cash equivalents | (20,938 |) 2,310 |
| Cash and cash equivalents, beginning of period | 94,114 | 82,971 |
| Cash and cash equivalents, end of period | \$73,176 | \$85,281 |

Supplemental disclosure of non-cash investing and financing activities:

| | | |
|---|-----|---------|
| Acquisition of buildings and land through capital lease | \$— | \$8,537 |
|---|-----|---------|

The accompanying notes are an integral part of these unaudited consolidated financial statements.

6

Table of Contents

BROOKS AUTOMATION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

1. Basis of Presentation

The unaudited consolidated financial statements of Brooks Automation, Inc. and its subsidiaries (“Brooks” or the “Company”) included herein have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany accounts and transactions have been eliminated. In the opinion of management, all material adjustments, which are of a normal and recurring nature, and necessary for a fair presentation of the financial position and results of operations for the periods presented have been reflected. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year.

In the second quarter of fiscal year 2014, the Company determined that its Granville-Phillips Gas Analysis & Vacuum Measurement (“Granville-Phillips”) business met the criteria to be reported as a discontinued operation. As a result, the Company’s historical financial statements have been revised to present the operating results of the Granville-Phillips business as a discontinued operation. The results of operations from the Granville-Phillips business are presented as “Income from discontinued operations, net of tax” in the Consolidated Statements of Operations. The discussion in the notes to these consolidated financial statements, unless otherwise noted, relate solely to the Company’s continuing operations (See Note 3).

Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) for the fiscal year ended September 30, 2014 (the “2014 Annual Report on Form 10-K”).

Use of Estimates and Summary of Significant Accounting Policies

The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue recognized using the percentage of completion method, pension obligations and stock-based compensation expense. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances, future projections that management believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

The Company’s significant accounting policies are described in Note 2 in the 2014 Annual Report on Form 10-K.

Recently Enacted Accounting Pronouncements

In July 2013, the Financial Accounting Standards Board (“FASB”) issued an amendment to the accounting guidance for presentation of unrecognized tax benefits. The prior guidance related to unrecognized tax benefits did not explicitly address financial statement presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists. The amended guidance eliminates the existing diversity in practice in the presentation of unrecognized tax benefits in these instances. Under the amended guidance, an unrecognized tax benefit, or a portion of an unrecognized tax benefit, will be presented in the financial statements as a reduction of a deferred tax asset when an operating loss carryforward, a similar tax loss or a tax credit carryforward exists, with limited exceptions. On October 1, 2014 the Company adopted this guidance, which had no impact on its financial position or results of operations.

In April 2014, the FASB issued an amendment to the accounting guidance for reporting discontinued operations. The amended guidance raises the threshold for disposals to qualify as a discontinued operation by requiring a component of an entity that is held for sale, or has been disposed of by sale, to represent a strategic shift that has or will have a major effect on operations and financial results. Under the amended guidance, a strategic shift could include the

disposal of a major line of business, a major geographical area, a major equity method investment or other major parts of an entity. In addition, the new guidance allows companies to have significant continuing involvement and continuing cash flows with the discontinued operation. The amended guidance is effective for fiscal years beginning on or after December 15, 2014. Early adoption is permitted for disposals, or classifications as held for sale, that have not been previously reported in financial statements. The Company has not considered this amended guidance in regard to the Granville-Phillips discontinued operation.

In May 2014, the FASB issued new accounting guidance for reporting revenue recognition. The guidance recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is

Table of Contents

expected to be received for those goods or services. The five step process may make it possible that more judgment and estimation is required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. This guidance is effective for fiscal years beginning after December 15, 2016. Early adoption is not permitted. The Company is evaluating the impact that the adoption of this guidance will have on its financial position and results of operations. In January 2015, the FASB issued new accounting guidance to simplify income statement classification by removing the concept of extraordinary items from GAAP. As a result, items that are both unusual and infrequent will no longer be separately reported net of tax after continuing operations. This guidance is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted. The adoption of this guidance will have no impact on the Company's financial position and results of operations.

In February 2015, the FASB issued an amendment to the accounting guidance for consolidations by changing the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. This guidance is effective for annual and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company is evaluating this standard and assessing the potential impact on its financial position and results of operations.

2. Stock-Based Compensation

The Company may issue restricted stock units and restricted stock awards collectively ("restricted stock units") and stock options which vest upon the satisfaction of a performance condition and/or a service condition. In addition, the Company issues shares to participating employees pursuant to an employee stock purchase plan.

The following table reflects stock-based compensation expense, excluding amounts related to discontinued operations, recorded during the three and six months ended March 31, 2015 and 2014 (in thousands):

| | Three months ended March 31, | | Six months ended March 31, | |
|------------------------------|---------------------------------|---------|-------------------------------|---------|
| | 2015 | 2014 | 2015 | 2014 |
| Restricted stock units | \$3,512 | \$3,683 | \$6,884 | \$6,293 |
| Employee stock purchase plan | 113 | 112 | 224 | 225 |
| | \$3,625 | \$3,795 | \$7,108 | \$6,518 |

The fair value per share of a restricted stock unit is equal to the quoted price of the Company's common stock on the date of grant, net of estimated forfeitures. The expense related to these awards is being recorded ratably over the vesting period. In addition, for stock-based awards where vesting is dependent upon achieving certain operating performance goals, the Company estimates the likelihood of achieving the performance goals against previously established performance targets in accordance with the Company's long-term equity incentive plan.

The Company grants restricted stock units that vest over a required service period and awards where vesting is dependent upon achieving certain operating performance goals. Restricted stock units granted with performance goals also have a required service period. The following table reflects restricted stock units granted, including awards related to the discontinued operation, during the six months ended March 31, 2015 and 2014:

| | Total Units | Time-Based and Board of Directors' Units | Performance-Based Units |
|---------------------------------|-------------|--|----------------------------|
| Six months ended March 31, 2015 | 1,443,959 | 619,709 | 824,250 |
| Six months ended March 31, 2014 | 1,409,557 | 601,432 | 808,125 |

Time-based and Board of Directors' Grants

Units granted with a required service period typically have three year vesting schedules in which, subject to the award holder meeting service requirements, one-third vest at the first anniversary of the date of grant, one-third vest at the second anniversary of the date of grant and one-third vest at the third anniversary of the date of grant. The Company granted 62,405 stock units and 77,557 stock units for the six months ended March 31, 2015 and 2014, respectively, to the Company's Board of Directors, which vest immediately.

Performance-based Grants

Performance-based units have performance criteria established by the Company's Human Resources and Compensation Committee and the Board of Directors. The criteria for performance-based awards are weighted and have minimum performance thresholds, which if not met result in no vesting as to that metric's weighted percentage.

8

Table of Contents

Performance-based awards granted in fiscal year 2014 included provisions where participants could achieve up to 200% of the targeted number of performance-based awards if the Company's performance exceeds the target. The measurement of achievement against performance-based units granted in fiscal year 2014 occurred at the end of fiscal year 2014 to determine the number of earned units eligible for subsequent vesting, in which one-half vest at the second anniversary of the date of grant and one-half vest at the third anniversary of the date of grant, subject to the award holder meeting service requirements.

The Company exceeded the fiscal year 2014 financial objectives associated with the performance-based awards which were granted in the first quarter of fiscal year 2014. Under the terms of the award, a total of 1,250,169 units could vest, subject to award holders satisfying the service requirement, which is an increase of 442,044 units over the target grant. Units granted to the employees of Granville-Phillips were forfeited upon completion of the sale.

Performance-based awards granted in fiscal year 2015 included provisions where participants could achieve up to 200% of the targeted number of performance-based awards if the Company's performance exceeds the target objectives.

Sixty percent of the performance-based units granted in fiscal year 2015 have certain performance criteria to be measured at the end of fiscal year 2015 to determine the number of earned units, in which one-half vest at the second anniversary of the date of grant and one-half vest at the third anniversary of the date of grant, subject to the award holder meeting service requirements. Forty percent of the performance-based units granted in fiscal year 2015 have certain performance criteria to be measured over a three year period to be measured at the end of fiscal year 2017 with any earned units vesting at the third anniversary of the date of the grant, subject to award holders satisfying the service requirement.

Stock Option Activity

The following table summarizes stock option activity for the six months ended March 31, 2015:

| | Number of Options | Weighted- Average Remaining Contractual Term | Weighted Average Exercise Price | Aggregate Intrinsic Value (In Thousands) |
|---------------------------------------|----------------------|---|---------------------------------------|--|
| Outstanding at September 30, 2014 | 5,550 | | \$ 13.20 | |
| Forfeited/expired | (5,550) |) | 13.20 | |
| Outstanding at March 31, 2015 | — | 0.0 years | \$— | \$— |
| Vested at March 31, 2015 | — | 0.0 years | \$— | \$— |
| Options exercisable at March 31, 2015 | — | 0.0 years | \$— | \$— |

No stock options were granted during the three or six months ended March 31, 2015 or 2014. There were no stock option exercises in the three or six months ended March 31, 2015 or 2014.

As of March 31, 2015, there was no future compensation cost related to stock options as all outstanding stock options have vested.

Restricted Stock Unit Activity

The following table summarizes restricted stock unit activity for the six months ended March 31, 2015:

| | Restricted Stock Units | Weighted Average Grant-Date Fair Value |
|-----------------------------------|---------------------------|---|
| Outstanding at September 30, 2014 | 2,726,485 | \$ 11.05 |
| Restricted stock units granted | 1,443,959 | 11.95 |
| Restricted stock units vested | (659,120) |) 11.93 |
| Restricted stock units canceled | (241,072) |) 10.52 |
| Outstanding at March 31, 2015 | 3,270,252 | \$ 11.90 |

The fair value of restricted stock units vested during the three months ended March 31, 2015 and 2014 was \$1.0 million and \$1.8 million, respectively. The fair value of restricted stock units vested during the six months ended

March 31, 2015 and 2014 was \$7.9 million and \$4.9 million, respectively.

As of March 31, 2015, the unrecognized compensation cost related to restricted stock units that is expected to vest is \$21.7 million and will be recognized over an estimated weighted average service period of 1.9 years.

Table of Contents

Employee Stock Purchase Plan

A total of 96,415 shares were purchased under the employee stock purchase plan during the three and six months ended March 31, 2015 for aggregate proceeds of \$0.9 million. A total of 115,132 shares were purchased under the employee stock purchase plan during the three and six months ended March 31, 2014 for aggregate proceeds of \$1.0 million.

3. Discontinued Operations

The Granville-Phillips business unit developed, manufactured, sold and serviced vacuum measurement and gas analysis instrumentation to semiconductor and non-semiconductor customers. In March 2014, the Company entered into an agreement to sell this business for \$87.0 million in cash. The sale was completed on May 30, 2014. The Company's historical financial statements have been revised to present the operating results of the Granville-Phillips business as a discontinued operation. The presentation of the Granville-Phillips business as a discontinued operation had no impact on previously reported net income (loss) or stockholders' equity.

4. Acquisitions

Acquisitions Completed in Fiscal Year 2015

On October 1, 2014, the Company acquired all of the outstanding stock of FluidX Ltd. ("FluidX"), a UK based provider of biological sample storage tubes and complementary bench-top instruments. The Company paid, in cash, aggregate merger consideration of \$15.5 million, net of cash acquired. The acquisition of FluidX provides the Company with the opportunity to enhance its existing capabilities with respect to biobanking solutions in the Brooks Life Science Systems segment.

The Company recorded the assets and liabilities associated with FluidX at their fair values as of the acquisition date. The preliminary amounts recorded were as follows (in thousands):

| | |
|--|----------|
| Accounts receivable | \$1,980 |
| Inventory | 2,857 |
| Prepaid and other current assets | 213 |
| Property, plant and equipment | 101 |
| Completed technology | 1,230 |
| Trademarks and trade names | 750 |
| Customer relationships | 4,810 |
| Goodwill | 8,247 |
| Accounts payable | (2,079) |
| Deferred revenue | (72) |
| Accrued liabilities | (992) |
| Long-term deferred tax liabilities | (1,540) |
| Total purchase price, net of cash acquired | \$15,505 |

The purchase price was allocated based on the fair value of the identified assets acquired and liabilities assumed as of the acquisition date from a market participant's perspective.

On January 23, 2015, the Company reached a settlement on certain working capital adjustments with the sellers of FluidX stock. On February 3, 2015, the Company paid such proceeds to the seller which increased the purchase price by \$0.1 million. At March 31, 2015, the Company had \$1.5 million in a general escrow account. The Company has not yet completed the final allocation of the consideration in connection with the acquisition of FluidX, but expects to do so in the measurement period.

The Company used the relief-from-royalty method, a form of the income approach, to value the trademarks and existing technology acquired. The principle behind this method is that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning that intangible asset. The Company used the excess-earnings method, a form of the income approach, to value the customer relationships acquired. The principle behind this method is that the value of the intangible asset is equal to the present value of the after-tax cash flows attributable to the intangible asset only. The weighted average amortization periods for intangible assets acquired in the FluidX acquisition are 7.0 years for each of completed technology, trademarks, and customer relationships. The

intangible assets acquired will be amortized using an accelerated depreciation method which approximates the pattern in which the economic benefits are expected to be realized.

10

Table of Contents

Goodwill represents the excess of the consideration transferred over the net assets acquired and has been assigned to the Company's Brooks Life Science Systems segment. Goodwill is primarily the result of expected synergies from combining the operations of FluidX with the Company. Goodwill arising from the acquisition of FluidX is not deductible for tax purposes.

The operating results of FluidX have been included in the results of operations for the Brooks Life Science Systems segment from the date of the acquisition. Revenue from FluidX for the three months ended March 31, 2015 was \$3.8 million and the net income was \$0.4 million. Revenue from FluidX for the six months ended March 31, 2015 was \$7.4 million and the net loss was \$0.1 million. The net income (loss) for the three and six months ended March 31, 2015 includes charges to expense of \$0.0 million and \$1.0 million, respectively, related to the step-up in value of the acquired inventories. The net income (loss) for the three and six months ended March 31, 2015 also includes amortization expense of \$0.3 million and \$0.7 million, respectively.

Acquisitions Completed in Fiscal Year 2014

On April 30, 2014, the Company acquired all the outstanding stock of Dynamic Micro Systems Semiconductor Equipment GmbH ("DMS"), a German provider of automated contamination control solutions for front opening unified pod, or "FOUP," carriers and reticle storage, targeted at improving yield of semiconductor processes at semiconductor fabrication plants. The Company paid, in cash, aggregate merger consideration of \$31.6 million, net of cash acquired. The acquisition of DMS expanded the Company's capabilities at semiconductor fabrication plants for yield improvement on new technology nodes.

The Company recorded the assets and liabilities associated with DMS at their fair values as of the acquisition date.

The preliminary amounts recorded were as follows (in thousands):

| | | |
|--|-----------|---|
| Accounts receivable | \$ 15,262 | |
| Inventory | 9,750 | |
| Prepaid and other current assets | 2,727 | |
| Property, plant and equipment | 2,049 | |
| Completed technology | 3,610 | |
| Customer relationships | 7,100 | |
| Goodwill | 11,939 | |
| Accounts payable | (10,393 |) |
| Accrued liabilities | (5,522 |) |
| Deferred revenue | (1,309 |) |
| Long-term deferred tax liabilities | (3,588 |) |
| Total purchase price, net of cash acquired | \$ 31,625 | |

The purchase price was allocated based on the fair value of the identified assets acquired and liabilities assumed as of the acquisition date from a market participant's perspective.

The Company reached settlement on certain working capital adjustments and other issues with the sellers of DMS' stock in the fourth quarter of fiscal year 2014. As a result of this settlement, the Company received \$2.2 million in the first quarter of fiscal year 2015 from certain escrows established at the date of acquisition. At March 31, 2015, \$2.7 million remained in escrow related to potential future claims against the sellers of DMS' stock. The Company has not yet completed the final allocation of the consideration paid in connection with the acquisition of DMS with respect to matters associated with the balances held in escrow and the potential impact of these matters on deferred tax liabilities. However, the Company expects to complete the final allocation within the measurement period.

The Company used the relief-from-royalty method, a form of the income approach, to value the completed technology acquired. The principle behind this method is that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning that intangible asset. The Company used the excess-earnings method, a form of the income approach, to value the customer relationships acquired. The principle behind this method is that the value of the intangible asset is equal to the present value of the after-tax cash flows attributable to the intangible asset only. The weighted average amortization periods for intangible assets acquired in the DMS acquisition are 5.0 years for completed technologies and 8.0 years for customer relationships. The intangible assets acquired will be

amortized using methods that approximate the pattern in which the economic benefits are expected to be realized, including variable declining balance and straight-line methods.

Goodwill represents the excess of the consideration transferred over the net assets acquired and has been assigned to the Company's Brooks Product Solutions segment. Goodwill is primarily the result of expected synergies from combining the operations of DMS with the Company. Goodwill arising from the acquisition of DMS is not deductible for tax purposes. In the first quarter of fiscal year 2015, the Company increased the opening goodwill balance by \$0.3 million as a result of a fair value

Table of Contents

adjustment recorded to inventory.

The operating results of DMS have been included in the results of operations for the Brooks Product Solutions segment from the date of the acquisition. Revenue from DMS for the three months ended March 31, 2015 was \$9.0 million and the net income was \$0.1 million. Revenue from DMS for the six months ended March 31, 2015 was \$16.1 million and the net loss was \$0.2 million. The net income for the three and six months ended March 31, 2015 includes charges to expense of \$0.0 million and \$0.6 million, respectively, related to the step-up in value of the acquired inventories. The net income for the three and six months ended March 31, 2015 also includes amortization of acquired intangible assets of \$0.6 million and \$1.1 million, respectively.

The following pro forma summary presents consolidated information of the Company as if the acquisition of DMS occurred on October 1, 2013 (in thousands):

| | Three months ended March 31, 2014 | Six months ended March 31, 2014 |
|--|---|---------------------------------------|
| Revenue | \$ 140,408 | \$ 259,853 |
| Net income attributable to Brooks Automation, Inc. | 3,467 | 2,860 |

The pro forma net income has been adjusted to reflect additional amortization from adjustments to intangible assets as if those adjustments had been applied as of October 1, 2013.

5. Goodwill and Intangible Assets

Goodwill represents the excess of net book value over the estimated fair value of net tangible and identifiable intangible assets of a reporting unit. The Company performs an annual impairment test of its goodwill on September 30 of each fiscal year unless interim indicators of impairment exist. The Company did not identify any indicators of goodwill impairment during the six month period ended March 31, 2015 that would warrant an interim test.

The components of the Company's goodwill, excluding amounts related to the discontinued operations, by business segment at March 31, 2015 are as follows (in thousands):

| | Brooks Product Solutions | Brooks Global Services | Brooks Life Science Systems | Other | Total |
|---|--------------------------------|------------------------------|-----------------------------------|-----------|------------|
| Gross goodwill at September 30, 2014 | \$494,275 | \$156,792 | \$47,378 | \$26,014 | \$724,459 |
| Less: aggregate impairment charges recorded | (437,706) | (151,238) | — | (26,014) | (614,958) |
| Goodwill, less accumulated impairments at September 30, 2014 | 56,569 | 5,554 | 47,378 | — | 109,501 |
| Acquisitions and adjustments during the six months ended March 31, 2015 | 516 | — | 8,247 | — | 8,763 |
| Goodwill, less accumulated impairments at March 31, 2015 | \$57,085 | \$5,554 | \$55,625 | \$— | \$118,264 |

Components of the Company's identifiable intangible assets, excluding amounts related to the discontinued operations, are as follows (in thousands):

| | March 31, 2015 | | | September 30, 2014 | | |
|----------------------------|----------------|-----------------------------|-------------------|--------------------|-----------------------------|-------------------|
| | Cost | Accumulated Amortization | Net Book Value | Cost | Accumulated Amortization | Net Book Value |
| Patents | \$7,808 | \$7,347 | \$461 | \$7,808 | \$7,300 | \$508 |
| Completed technology | 58,409 | 44,141 | 14,268 | 57,155 | 41,539 | 15,616 |
| Trademarks and trade names | 4,240 | 3,546 | 694 | 3,496 | 3,496 | — |
| Customer relationships | 77,916 | 33,646 | 44,270 | 73,389 | 29,963 | 43,426 |
| | \$148,373 | \$88,680 | \$59,693 | \$141,848 | \$82,298 | \$59,550 |

The Company recorded an increase to goodwill in the amount of \$8.8 million during the six months ended March 31, 2015. This increase includes \$8.2 million related to the acquisition of FluidX, representing the excess of the

consideration transferred over the net assets acquired from FluidX. This increase also includes \$0.3 million due to a fair value adjustment recorded to DMS inventory, resulting in an increase to opening goodwill. The Company is required to test certain long-lived assets when indicators of impairment are present. The Company

Table of Contents

evaluated the existence of impairment indicators on long-lived assets for the six months ended March 31, 2015 and determined that the indicators were not present. The Company initially determined that impairment indicators were present for the long-lived assets related to the Celigo product line as of September 30, 2013. The long-lived assets in question were tested for recoverability, which resulted in the conclusion that the carrying amounts of the assets were not fully recoverable. As a result of this analysis, management determined that an impairment loss of \$2.0 million had occurred as of September 30, 2013. The Company revised its estimate of the fair value of these assets during the three months ended December 31, 2013 and determined that an additional impairment loss of \$0.4 million, representing the remaining carrying value of the long-lived assets, was required. These impairment losses were recorded in the Brooks Life Science Systems segment. The Company completed the sale of the Celigo product line in the second quarter of fiscal year 2014.

6. Income Taxes

The Company recorded an income tax provision (benefit) of \$1.6 million and \$(1.6) million for the three and six months ended March 31, 2015, respectively. The tax provision is driven by global income during the current quarter and interest related to unrecognized tax benefits. The tax benefit is driven by U.S. pre-tax losses in the first quarter of fiscal 2015, \$0.6 million of reductions in unrecognized tax benefits resulting from the expiration of the statute of limitations in various foreign jurisdictions and \$0.9 million of tax benefits resulting from the reinstatement of the U.S. federal research and development tax credit, retroactive to January 1, 2014. These benefits are partially offset by foreign income taxes and interest related to unrecognized tax benefits.

The Company recorded an income tax provision of \$1.1 million and \$1.9 million for the three and six months ended March 31, 2014, respectively. These tax provisions substantially consist of U.S. and foreign income taxes, as well as interest related to unrecognized tax benefits.

The Company evaluates the realizability of its deferred tax assets by jurisdiction and assesses the need for a valuation allowance on a quarterly basis. As of March 31, 2015, the Company has continued to maintain a valuation allowance in the U.S. against certain tax credits and state net operating losses due to the uncertainty of their realization based on long-term Company forecasts and the expiration dates on these attributes. The Company has also continued to maintain a valuation allowance in certain jurisdictions that have not generated historical cumulative profitability. The Company is subject to U.S. federal income tax and various state, local and foreign income taxes in various jurisdictions. The amount of income taxes paid is subject to the Company's interpretation of applicable tax laws in the jurisdictions in which it files. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. The Company has income tax audits in progress in various jurisdictions in which it operates. In the Company's U.S. and foreign jurisdictions, the years that may be examined vary, with the earliest tax year being 2008. Based on the outcome of these examinations, or the expiration of statutes of limitations for specific jurisdictions, the related unrecognized tax benefits could change from those recorded in the Company's Consolidated Balance Sheets. It is reasonably possible that the unrecognized tax benefit will be reduced by approximately \$1.3 million during the next twelve months as the result of the expiration of statutes of limitations.

7. Earnings per Share

Below is a reconciliation of weighted average common shares outstanding for purposes of calculating basic and diluted earnings per share (in thousands):

| | Three months ended March 31, | | Six months ended March 31, | |
|---|---------------------------------|--------|-------------------------------|--------|
| | 2015 | 2014 | 2015 | 2014 |
| Weighted average common shares outstanding used in computing basic earnings per share | 67,387 | 66,646 | 67,255 | 66,499 |
| Dilutive common stock options and restricted stock units | 1,027 | 859 | — | 884 |
| Weighted average common shares outstanding for purposes of computing diluted earnings per share | 68,414 | 67,505 | 67,255 | 67,383 |

Options to purchase approximately 2,000 and 16,000 shares of common stock and 552,000 and 0 restricted stock units were excluded from the computation of diluted earnings per share attributable to common stockholders for the three

months ended March 31, 2015 and 2014, respectively, as their effect would be anti-dilutive. In addition, options to purchase approximately 16,000 shares of common stock and 0 shares of restricted stock were excluded from the computation of diluted earnings per share attributable to common stockholders for the six months ended March 31, 2014, as their effect would be anti-dilutive. All unvested shares of restricted stock units were excluded from the computation of diluted earnings per share for the six months ended March 31, 2015 as a result of the net loss for that period.

Table of Contents

8. Segment Information

The Company reports financial results in three segments: Brooks Product Solutions, Brooks Global Services and Brooks Life Science Systems. A description of segments is included in the 2014 Annual Report on Form 10-K, included in Note 18.

The Company evaluates the performance of, and allocates resources to, each of its segments based on their revenues, operating income (loss) and returns on invested assets. Operating income (loss) for each segment includes selling, general and administrative expenses directly attributable to the segment. Other unallocated corporate expenses, amortization of acquired intangible assets (excluding completed technology) and restructuring and other charges are excluded from the segments' operating income (loss). The Company's indirect overhead costs, which include various general and administrative expenses, are allocated among the segments based upon multiple cost drivers associated with the respective administrative function, including segment revenue, segment headcount, or an analysis of the segments that benefit from a specific administrative function. Segment assets exclude cash, cash equivalents, marketable securities, deferred tax assets and equity method investments.

Table of Contents

Financial information for the Company's business segments, excluding amounts related to the discontinued operations, is as follows (in thousands):

| | Brooks Product Solutions | Brooks Global Services | Brooks Life Science Systems | Total |
|-----------------------------------|--------------------------------|------------------------------|-----------------------------------|-----------|
| Three months ended March 31, 2015 | | | | |
| Revenue | | | | |
| Product | \$98,958 | \$4,128 | \$13,309 | \$116,395 |
| Services | — | 18,709 | 4,209 | 22,918 |
| | \$98,958 | \$22,837 | \$17,518 | \$139,313 |
| Gross profit | \$33,995 | \$7,043 | \$4,987 | \$46,025 |
| Segment operating income (loss) | \$7,995 | \$2,108 | \$(4,391) |) \$5,712 |
| Three months ended March 31, 2014 | | | | |
| Revenue | | | | |
| Product | \$89,897 | \$4,213 | \$8,424 | \$102,534 |
| Services | — | 19,178 | 4,188 | 23,366 |
| | \$89,897 | \$23,391 | \$12,612 | \$125,900 |
| Gross profit | \$31,960 | \$7,676 | \$4,662 | \$44,298 |
| Segment operating income (loss) | \$6,127 | \$2,248 | \$(3,565) |) \$4,810 |
| Six months ended March 31, 2015 | | | | |
| Revenue | | | | |
| Product | \$181,814 | \$8,236 | \$26,075 | \$216,125 |
| Services | — | 37,798 | 8,126 | 45,924 |
| | \$181,814 | \$46,034 | \$34,201 | \$262,049 |
| Gross profit | \$60,917 | \$15,506 | \$8,690 | \$85,113 |
| Segment operating income (loss) | \$8,457 | \$5,661 | \$(9,907) |) \$4,211 |
| Six months ended March 31, 2014 | | | | |
| Revenue | | | | |
| Product | \$171,453 | \$7,652 | \$16,559 | \$195,664 |
| Services | — | 39,058 | 8,250 | 47,308 |
| | \$171,453 | \$46,710 | \$24,809 | \$242,972 |
| Gross profit | \$60,461 | \$15,501 | \$9,227 | \$85,189 |
| Segment operating income (loss) | \$10,455 | \$5,091 | \$(7,040) |) \$8,506 |
| Assets | | | | |
| March 31, 2015 | \$259,393 | \$55,809 | \$117,249 | \$432,451 |
| September 30, 2014 | \$252,944 | \$58,678 | \$103,498 | \$415,120 |

Table of Contents

A reconciliation of the Company's reportable segment operating income (loss) to the corresponding consolidated amounts for the three and six month periods ended March 31, 2015 and 2014 is as follows (in thousands):

| | Three months ended | | Six months ended | |
|--|--------------------|---------|------------------|---------|
| | March 31, | | March 31, | |
| | 2015 | 2014 | 2015 | 2014 |
| Segment operating income | \$5,712 | \$4,810 | \$4,211 | \$8,506 |
| Amortization of acquired intangible assets | 1,914 | 1,460 | 3,826 | 2,916 |
| Restructuring and other charges | 685 | 772 | 3,353 | 1,519 |
| Other unallocated corporate expenses | 60 | 182 | 459 | 217 |
| Total operating income (loss) | \$3,053 | \$2,396 | \$(3,427) | \$3,854 |

A reconciliation of the Company's reportable segment assets to the corresponding consolidated amounts as of March 31, 2015 and September 30, 2014 is as follows (in thousands):

| | March 31, | September 30, |
|--|-----------|---------------|
| | 2015 | 2014 |
| Segment assets | \$432,451 | \$ 415,120 |
| Cash, cash equivalents and marketable securities | 207,104 | 245,456 |
| Deferred tax assets | 88,466 | 86,572 |
| Equity method investments | 27,027 | 28,944 |
| Other unallocated corporate net assets | 1,907 | 1,946 |
| Total assets | \$756,955 | \$ 778,038 |

9. Significant Customers

The Company had one customer that accounted for more than 10% of its revenue, at 11% and 10%, in the three months ended March 31, 2015 and 2014, respectively. The Company had one customer that accounted for more than 10% of its revenue at 12%, in each of the six months ended March 31, 2015 and 2014. The Company did not have any customers that accounted for more than 10% of its accounts receivable balance at March 31, 2015 or September 30, 2014.

For purposes of determining the percentage of revenue from any original equipment manufacturer ("OEM") customer, the Company does not include revenue from products sold to a contract manufacturer customer which in turn sells to the OEM. If the Company included revenue from products sold to contract manufacturer customers supporting the Company's OEM customers, the percentage of the Company's total revenue derived from certain OEM customers would be higher.

10. Restructuring and Other Charges

The Company recorded a restructuring charge of \$0.7 million for the three months ended March 31, 2015 related to severance costs. These severance costs were driven by actions taken to consolidate global functional support roles and transition the manufacturing of certain product sub-assemblies to third party contract manufacturers within the Brooks Life Science Systems segment. The Company incurred additional severance costs within the Brooks Product Solutions segment related to the transition of manufacturing certain products from the Company's facility in Mistelgau, Germany to a third party contract manufacturer. The Company's manufacturing site in Germany is expected to close in 2016.

The Company recorded a restructuring charge of \$3.4 million for the six months ended March 31, 2015, which included \$2.1 million of severance costs and \$1.2 million of facility exit costs. Included in these restructuring charges are the severance costs described above along with \$2.7 million of restructuring costs for the three months ended December 31, 2014 as a result of actions taken to reduce the Company's workforce in order to improve its cost structure and ongoing cost discipline. These restructuring charges related primarily to severance costs of \$1.5 million and facility exit related costs of \$1.2 million. The reduction in workforce was primarily the result of consolidation of positions in the United States and Germany, including reductions related to the integration of the Company's acquisition of DMS. The facility exit costs were due to the outsourcing of manufacturing certain products in the Company's line of Polycold cryochillers and compressors within the United States to a third party contract

manufacturer. The facility exit costs were estimated according to future lease payments and operating costs to be paid until the termination of the lease.

The Company recorded a restructuring charge of \$0.8 million and \$1.5 million for the three and six months ended March 31, 2014, respectively. These restructuring costs consisted primarily of severance and other workforce-related costs resulting from the consolidation of certain administrative functions in the Brooks Life Science Systems segment, the on-going

Table of Contents

transition of manufacturing certain of the Company's Polycold products to a third party contract manufacturer and other programs designed to improve the Company's cost structure.

The activity for the three and six months ended March 31, 2015 and 2014 related to the Company's restructuring-related accruals, excluding amounts related to the discontinued operations, is summarized below (in thousands):

| | Activity — Three months ended March 31, 2015 | | | |
|----------------------|--|---------|-------------|------------|
| | Balance at | | Utilization | Balance at |
| | December 31, | Expense | | March 31, |
| | 2014 | | | 2015 |
| Facilities and other | \$1,175 | \$— | \$(271) | \$904 |
| Workforce-related | 2,753 | 685 | (1,045) | 2,393 |
| | \$3,928 | \$685 | \$(1,316) | \$3,297 |

| | Activity — Three Months Ended March 31, 2014 | | | |
|----------------------|--|---------|-------------|------------|
| | Balance at | | Utilization | Balance at |
| | December 31, | Expense | | March 31, |
| | 2013 | | | 2014 |
| Facilities and other | \$57 | \$7 | \$(64) | \$— |
| Workforce-related | 1,405 | 765 | (618) | 1,552 |
| | \$1,462 | \$772 | \$(682) | \$1,552 |

| | Activity — Six months ended March 31, 2015 | | | |
|----------------------|--|---------|-------------|------------|
| | Balance at | | Utilization | Balance at |
| | September | Expense | | March 31, |
| | 30, | | | 2015 |
| | 2014 | | | |
| Facilities and other | \$71 | \$1,205 | \$(372) | \$904 |
| Workforce-related | 3,404 | 2,148 | (3,159) | 2,393 |
| | \$3,475 | \$3,353 | \$(3,531) | \$3,297 |

| | Activity — Six months ended March 31, 2014 | | | |
|----------------------|--|---------|-------------|------------|
| | Balance at | | Utilization | Balance at |
| | September | Expense | | March 31, |
| | 30, | | | 2014 |
| | 2013 | | | |
| Facilities and other | \$155 | \$13 | \$(168) | \$— |
| Workforce-related | 1,257 | 1,506 | (1,211) | 1,552 |
| | \$1,412 | \$1,519 | \$(1,379) | \$1,552 |

The Company anticipates that the accrued restructuring costs at March 31, 2015 will be substantially paid in the next twelve months.

11. Employee Benefit Plans

The Company has two active defined benefit pension plans (collectively, the "Plans"). The Plans cover substantially all of the Company's employees in Switzerland and Taiwan. Retirement benefits are generally earned based on years of service and compensation during active employment; however, the level of benefits varies within the Plans. Eligibility is determined in accordance with local statutory requirements.

Table of Contents

The components of the Company's net pension cost for the three and six months ended March 31, 2015 and 2014 are as follows (in thousands):

| | Three months ended | | Six months ended | |
|---------------------------|--------------------|-------|------------------|--------|
| | March 31, | | March 31, | |
| | 2015 | 2014 | 2015 | 2014 |
| Service cost | \$129 | \$102 | \$248 | \$202 |
| Interest cost | 33 | 39 | 64 | 78 |
| Amortization of losses | — | — | — | 1 |
| Expected return on assets | (58 |) (55 |) (111 |) (108 |
| Net periodic pension cost | \$104 | \$86 | \$201 | \$173 |

12. Other Balance Sheet Information

The following is a summary of accounts receivable at March 31, 2015 and September 30, 2014 (in thousands):

| | March 31, | September 30, |
|--------------------------------------|-----------|---------------|
| | 2015 | 2014 |
| Accounts receivable | \$96,066 | \$81,270 |
| Less allowance for doubtful accounts | (1,261 |) (1,031 |
| Less allowance for sales returns | (126 |) (133 |
| | \$94,679 | \$80,106 |

The following is a summary of inventories at March 31, 2015 and September 30, 2014, excluding amounts related to discontinued operations (in thousands):

| | March 31, | September 30, |
|-----------------------------------|-----------|---------------|
| | 2015 | 2014 |
| Inventories | | |
| Raw materials and purchased parts | \$55,456 | \$57,250 |
| Work-in-process | 19,600 | 20,068 |
| Finished goods | 15,502 | 16,249 |
| | \$90,558 | \$93,567 |

Reserves for excess and obsolete inventory were \$24.9 million and \$26.0 million, excluding amounts related to discontinued operations, at March 31, 2015 and September 30, 2014, respectively.

The Company provides for the estimated cost of product warranties, primarily from historical information, at the time product revenue is recognized and retrofit accruals at the time retrofit programs are established. The Company's warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure, and supplier warranties on parts delivered to the Company.

Product warranty and retrofit activity on a gross basis for the three and six months ended March 31, 2015 and 2014, excluding amounts related to discontinued operations, is as follows (in thousands):

Activity - Three months ended March 31, 2015

| Balance at | Adjustments for | Accruals | Costs Incurred | Balance at |
|--------------|-------------------------------|----------|----------------|------------|
| December 31, | Acquisitions and Divestitures | | | March 31, |
| 2014 | | | | 2015 |
| \$6,255 | \$ — | \$2,428 | \$(2,480) |) \$6,203 |

Activity - Three months ended March 31, 2014

| Balance at | Adjustments for | Accruals | Costs Incurred | Balance at |
|--------------|-------------------------------|----------|----------------|------------|
| December 31, | Acquisitions and Divestitures | | | March 31, |
| 2013 | | | | 2014 |
| \$6,762 | \$ — | \$2,275 | \$(2,718) |) \$6,319 |

Table of Contents

Activity - Six months ended March 31, 2015

| Balance at September 30, 2014 | Adjustments for Acquisitions and Divestitures | Accruals | Costs Incurred | Balance at March 31, 2015 |
|-------------------------------------|--|----------|----------------|---------------------------------|
| \$6,499 | \$ 81 | \$5,145 | \$(5,522 |) \$6,203 |

Activity - Six months ended March 31, 2014

| Balance at September 30, 2013 | Adjustments for Acquisitions and Divestitures | Accruals | Costs Incurred | Balance at March 31, 2014 |
|-------------------------------------|--|----------|----------------|---------------------------------|
| \$7,260 | \$ — | \$4,150 | \$(5,091 |) \$6,319 |

13. Equity Method Investments

The Company accounts for certain of its investments using the equity method. Under this method of accounting, the Company records in income its proportionate share of the earnings (losses) of the investee with a corresponding increase (decrease) in the carrying value of the investment.

BioCision, LLC

In March 2014, the Company acquired a 22% equity interest in BioCision, LLC (“BioCision”), a privately-held company based in Larkspur, California, for \$4.0 million. BioCision develops, manufactures and markets cell cryopreservation products used to improve and standardize the tools and methods for biomaterial sample handling. The Company determined that the level of equity investment at risk was not sufficient for BioCision to finance its activities without additional financial support and as a result, represented a variable interest entity. However, the Company does not have the power to direct the activities that most significantly impact BioCision’s economic performance, and therefore does not qualify as the primary beneficiary. As such, the Company concluded that BioCision will not be consolidated in the Company’s financial statements.

For the three and six months ended March 31, 2015, the Company recorded a loss associated with BioCision of \$0.3 million and \$0.5 million. At March 31, 2015, the carrying value of the investment in BioCision in the Company’s Consolidated Balance Sheet was \$3.2 million.

The Company purchased BioCision five-year convertible debt securities with a warrant agreement to purchase preferred units of BioCision for a total of \$2.5 million on December 22, 2014 and February 2, 2015, resulting in a total purchase price of \$5.0 million. The convertible debt securities were accounted for under the fair value method, and were recorded at fair value. The warrants were accounted for as a derivative and were recorded at fair value. The Company will re-measure the fair value of the BioCision convertible debt securities and warrants each reporting period, and the respective gain or loss will be recognized in earnings. Interest accrues on the convertible debt securities at a rate of 9% per annum, and is due with the principal upon maturity. As a result of the funding, the Company reconsidered whether BioCision represents a variable interest entity, which is subject to consolidation. The Company concluded that the level of equity investment at risk is still insufficient for BioCision to finance its activities without additional support, thus will remain a variable interest entity. However, the Company still does not have the power to direct the activities that most significantly impact BioCision’s economic performance, and therefore still does not qualify as the primary beneficiary. As such, the Company concluded that BioCision will not be consolidated in the Company’s financial statements. As of March 31, 2015, the fair value of the convertible debt securities and warrants was \$5.2 million and \$70,000, respectively. For further information regarding the convertible debt securities and warrants, see Note 17, “Fair Value Measurements”.

Table of Contents

ULVAC Cryogenics, Inc.

The Company participates in a 50% joint venture, ULVAC Cryogenics, Inc. (“UCI”), with ULVAC Corporation of Chigasaki, Japan. UCI manufactures and sells cryogenic vacuum pumps, principally to ULVAC Corporation. For the three months ended March 31, 2015 and 2014, the Company recorded income associated with UCI of \$16,000 and \$0.5 million, respectively. For the six months ended March 31, 2015 and 2014, the Company recorded income associated with UCI of \$0.4 million and \$1.2 million, respectively. At March 31, 2015, the carrying value of UCI in the Company’s Consolidated Balance Sheet was \$21.9 million. For each of the three months ended March 31, 2015 and 2014, management fee payments received by the Company from UCI were \$0.2 million. For each of the six months ended March 31, 2015 and 2014, management fee payments received by the Company from UCI were \$0.3 million. For the three months ended March 31, 2015 and 2014, the Company incurred charges from UCI for products or services of \$46,000 and \$37,000, respectively. For each of the six months ended March 31, 2015 and 2014, the Company incurred charges from UCI for products or services of \$0.1 million. At March 31, 2015 and September 30, 2014, the Company owed UCI \$46,000 and \$79,000, respectively, in connection with accounts payable for unpaid products and services.

Yaskawa Brooks Automation, Inc.

The Company participates in a 50% joint venture with Yaskawa Electric Corporation (“Yaskawa”) called Yaskawa Brooks Automation, Inc. (“YBA”) to exclusively market and sell Yaskawa’s semiconductor robotics products and Brooks’ automation hardware products to semiconductor customers in Japan. During the first quarter of fiscal year 2015, the Company and Yaskawa agreed in principle to dissolve the joint venture. On January 22, 2015, the Company entered into an agreement with YBA to facilitate the acquisition of certain assets and certain liabilities by the Company’s subsidiary in Japan. In accordance with the agreement, on March 20, 2015 the Company’s subsidiary in Japan received the net assets of YBA for cash consideration of approximately \$1.8 million. The Company recorded the assets received and liabilities assumed from YBA at their fair value as of the acquisition date. As a result of the transaction, the Company recorded \$0.2 million of goodwill, representing the excess of the consideration transferred over the net assets acquired. The cash received by YBA will be used to pay off remaining liabilities and the liquidation costs of YBA. Any remaining cash after making these payments will be distributed to the equity partners in the form of a dividend, which is expected to occur by the end of fiscal year 2015.

The Company recorded \$0.2 million of income associated with YBA for the three months ended March 31, 2015, compared to \$35,000, for the three months ended March 31, 2014. For the six months ended March 31, 2015 and 2014, the Company recorded income (expense) associated with YBA of \$(0.5) million and \$17,000, respectively. At March 31, 2015, the carrying value of YBA in the Company’s Consolidated Balance Sheet was \$1.9 million. For the three months ended March 31, 2015 and 2014, revenue earned by the Company from YBA was \$1.0 million and \$2.1 million, respectively. For the six months ended March 31, 2015 and 2014, revenue earned by the Company from YBA was \$2.1 million and \$2.8 million, respectively. For the three months ended March 31, 2015 and 2014, the Company incurred charges from YBA for products or services of \$0.5 million and \$0.2 million, respectively. For the six months ended March 31, 2015 and 2014, the Company incurred charges from YBA for products or services of \$0.9 million and \$0.3 million, respectively.

The amount due from YBA included in accounts receivable at March 31, 2015 and September 30, 2014 was \$0.0 million and \$2.1 million, respectively. At March 31, 2015 and September 30, 2014, the Company owed YBA \$0.0 million and \$0.1 million, respectively, in connection with accounts payable for unpaid products and services. The Company expects the YBA dissolution to be completed within the fourth quarter of fiscal year 2015.

14. Note Receivable

In 2012, the Company provided a strategic partner (the “Borrower”) a loan of \$3.0 million to support the Borrower's future product development and other working capital requirements. The loan bears interest at a rate of 9% and the outstanding principal and interest was payable in May 2015. The Company also received a warrant to purchase the Borrower's common stock in the event of an equity offering by the Borrower and certain other rights related to conversion of the loan, first refusal to acquire the Borrower and a redemption premium. The loan was secured by a security agreement granting the Company a first-priority security interest in all of the assets of the Borrower.

The Company determined that the level of equity investment at risk was not sufficient for the entity to finance its activities without additional financial support and as a result, represented a variable interest entity. However, the Company does not have the power to direct the activities that most significantly impact the Borrower's economic performance and would not absorb the majority of the expected losses from the Borrower, and therefore does not qualify as the primary beneficiary. The Company has no future contractual funding commitments to the Borrower and as a result, the Company's exposure to loss was limited to the outstanding principal and interest under the loan. During the third quarter of fiscal year 2014, the Borrower informed the Company of its intent to secure additional funding from an investment program funded by the Commonwealth of Massachusetts designed to support early-stage

Table of Contents

companies. In connection with the Borrower's efforts to secure additional financing, the Company agreed to subordinate its security interest in the assets of the Borrower to the new lender. Additionally, the Company agreed to extend the due date of its loan by approximately 5 years, to September 2019, in order to coincide with the due date of the new loan. The amended loan has a stated interest rate of 10%.

In connection with its efforts to secure additional financial support, the Borrower developed revised assumptions about its future cash flows. Based on the information provided by the Borrower, and the subordination to the new lender, the Company determined it was probable that it would not recover all amounts due from the loan and recorded an impairment charge of \$2.6 million in the third quarter of fiscal year 2014. The impairment charge, which included the warrant write-off, was recorded in the Consolidated Statements of Operations in selling, general and administrative expenses.

The fair value of the loan was determined by considering the fair value of the collateral using valuation techniques, principally the discounted cash flow method, less amounts committed by the new lender. The observable inputs used in the Company's analysis were limited primarily to the discount rate, which was based on a rate commensurate with the risks and uncertainties of the Borrower. As a result, the fair value of the loan at March 31, 2015 could be different under different conditions or different assumptions, including the varying assumptions regarding future cash flows of the Borrower or discount rates.

15. Derivative Instruments

The Company has transactions and balances denominated in currencies other than the U.S. dollar. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. These transactions and balances, including short-term advances between the Company and its subsidiaries, subject the Company's operations to exposure from exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company mitigates the impact of potential currency translation gains and losses on short-term intercompany advances through timely settlement of each transaction, generally within 30 days.

The Company also enters into foreign exchange contracts to reduce its exposure to currency translation. Under forward contract arrangements, the Company typically agrees to purchase a fixed amount of U.S. dollars in exchange for a fixed amount of a foreign currency on specified dates with maturities of three months or less. These transactions do not qualify for hedge accounting.

Net gains and losses recorded as a component of "Other income, net" in the Consolidated Statements of Operations related to these contracts for the three and six months ended March 31, 2015 and 2014 is as follows (in thousands):

| | Three months ended | | Six months ended | |
|---|--------------------|----------|------------------|----------|
| | March 31, | | March 31, | |
| | 2015 | 2014 | 2015 | 2014 |
| Realized gains (losses) on derivative instruments not designated as hedging instruments | \$126 | \$(154) | \$426 | \$(107) |

Table of Contents

The Company had the following notional amounts outstanding under foreign currency contracts that do not qualify for hedge accounting at March 31, 2015 and September 30, 2014 (in thousands):

March 31, 2015:

| Buy Currency | Notional Amount of Buy Currency | Sell Currency | Maturity | Notional Amount of Sell Currency | Fair Value of Assets | Fair Value of Liabilities |
|---------------|---------------------------------|----------------|--------------------|----------------------------------|----------------------|---------------------------|
| U.S. Dollar | 1,343 | Japanese Yen | April to June 2015 | 160,000 | \$ 5 | \$— |
| British Pound | 1,098 | Euro | April 2015 | 1,500 | — | 7 |
| U.S. Dollar | 673 | Taiwan Dollar | April 2015 | 21,000 | 2 | — |
| U.S. Dollar | 1,248 | British Pound | April 2015 | 840 | — | 1 |
| Euro | 5,100 | U.S. Dollar | April 2015 | 5,560 | 23 | |
| Korean Won | 330,000 | U.S. Dollar | April 2015 | 299 | — | — |
| U.S. Dollar | 403 | Japanese Yen | April 2015 | 48,000 | 1 | — |
| U.S. Dollar | 603 | Israeli Shekel | April 2015 | 2,400 | — | 7 |
| | | | | | \$ 31 | \$ 15 |

September 30, 2014:

| Buy Currency | Notional Amount of Buy Currency | Sell Currency | Maturity | Notional Amount of Sell Currency | Fair Value of Assets | Fair Value of Liabilities |
|---------------|---------------------------------|----------------|-------------------------------|----------------------------------|----------------------|---------------------------|
| U.S. Dollar | 1,736 | Japanese Yen | October 2014 to December 2014 | 190,000 | \$— | \$ 11 |
| U.S. Dollar | 1,395 | Euro | October 2014 | 1,100 | — | 16 |
| U.S. Dollar | 656 | Taiwan Dollar | October 2014 | 20,000 | — | 5 |
| U.S. Dollar | 650 | British Pound | October 2014 | 400 | — | 5 |
| U.S. Dollar | 731 | Israeli Shekel | October 2014 | 2,700 | — | 5 |
| U.S. Dollar | 76 | Korean Won | October 2014 | 80,000 | — | 1 |
| British Pound | 3,513 | Euro | October 2014 | 4,500 | — | 15 |
| | | | | | \$— | \$ 58 |

The fair values of the forward contracts described above are recorded in the Company's Consolidated Balance Sheets as "Prepaid expenses and other current assets" and "Accrued expenses and other current liabilities".

Stock Warrants

The BioCision warrant agreements contain net share settlement provisions, which permit the Company to pay the warrant exercise price using shares issuable under the warrants ("cashless exercise"). The value of the stock warrants will fluctuate primarily in relation to the value of BioCision's underlying securities, either providing an appreciation in value or potentially expiring with no value. Gains and losses on the revaluation of the stock warrants are recognized in "Other income, net" on the Consolidated Statements of Income. See Note 17 "Fair Value Measurements" for further information regarding the fair value of the stock warrants.

16. Marketable Securities

The Company invests in marketable securities and classifies them as available-for-sale. The Company records these securities at fair value. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date. At the time that the maturity dates of these investments become one year or less, the securities are reclassified to current assets. Unrealized gains and losses are excluded from earnings and reported as a separate component of accumulated other comprehensive income until the security is sold or matures. At the time of sale, any gains or losses, calculated by the specific identification method, will be recognized as a component of operating results.

Table of Contents

The following is a summary of marketable securities (included in short and long-term marketable securities in the Consolidated Balance Sheets), including accrued interest receivable, as of March 31, 2015 and September 30, 2014 (in thousands):

| | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value |
|--|-------------------|------------------------------|-------------------------------|-------------|
| March 31, 2015: | | | | |
| U.S. Treasury securities and obligations of U.S. government agencies | \$27,402 | \$17 | \$(2) |) \$27,417 |
| Corporate securities | 61,377 | 26 | (38) |) 61,365 |
| Mortgage-backed securities | 911 | 30 | — | 941 |
| Other debt securities | 6,270 | 2 | — | 6,272 |
| Municipal securities | 19,936 | 2 | (14) |) 19,924 |
| Bank certificate of deposits | 16,946 | 1,063 | — | 18,009 |
| | \$132,842 | \$1,140 | \$(54) |) \$133,928 |
| September 30, 2014: | | | | |
| U.S. Treasury securities and obligations of U.S. government agencies | \$26,052 | \$1 | \$(39) |) \$26,014 |
| Corporate securities | 74,614 | 23 | (174) |) 74,463 |
| Mortgage-backed securities | 964 | 36 | — | 1,000 |
| Other debt securities | 7,358 | — | (10) |) 7,348 |
| Municipal securities | 15,888 | 1 | (16) |) 15,873 |
| Bank certificate of deposits | 26,645 | 2 | (3) |) 26,644 |
| | \$151,521 | \$63 | \$(242) |) \$151,342 |

The fair value of the marketable securities at March 31, 2015 by contractual maturity, are shown below (in thousands):

| | Fair Value |
|---------------------------------------|------------|
| Due in one year or less | \$69,327 |
| Due after one year through five years | 61,247 |
| Due after ten years | 3,354 |
| | \$133,928 |

Expected maturities could differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

17. Fair Value Measurements

The fair value measurement guidance establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset and liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Table of Contents

Assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2015 and September 30, 2014 are summarized as follows (in thousands):

| Description | March 31, 2015 | Fair Value Measurements at Reporting Date Using | | |
|-------------------------------|-------------------|---|---|---|
| | | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |
| Assets | | | | |
| Cash equivalents | \$ 10,404 | \$ 10,154 | \$ 250 | \$ — |
| Available-for-sale securities | 133,928 | — | 133,928 | — |
| Foreign exchange contracts | 31 | — | 31 | — |
| Convertible debt securities | 5,207 | — | — | 5,207 |
| Stock warrants | 70 | — | — | 70 |
| Total Assets | \$ 149,640 | \$ 10,154 | \$ 134,209 | \$ 5,277 |
| Liabilities | | | | |
| Foreign exchange contracts | \$ 15 | \$ — | \$ 15 | \$ — |

The convertible debt securities and stock are included in "Other assets" in the Consolidated Balance Sheets.

| Description | September 30, 2014 | Fair Value Measurements at Reporting Date Using | | |
|-------------------------------|-----------------------|---|---|---|
| | | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |
| Assets | | | | |
| Cash equivalents | \$ 6,404 | \$ 5,166 | \$ 1,238 | \$ — |
| Available-for-sale securities | 151,342 | — | 151,342 | — |
| Total Assets | \$ 157,746 | \$ 5,166 | \$ 152,580 | \$ — |
| Liabilities | | | | |
| Foreign exchange contracts | \$ 58 | \$ — | \$ 58 | \$ — |

Cash Equivalents

Cash equivalents of \$10.2 million and \$5.2 million at March 31, 2015 and September 30, 2014, respectively, consisting of Money Market Funds, are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Cash equivalents of \$0.3 million and \$1.2 million at March 31, 2015 and September 30, 2014, respectively, consisting primarily of Bank Certificate of Deposits, are classified within Level 2 of the hierarchy because they are not actively traded.

Available-For-Sale Securities

Available-for-sale securities of \$133.9 million and \$151.3 million at March 31, 2015 and September 30, 2014, respectively, consisting of Municipal Securities, Bank Certificate of Deposits, Commercial Paper, U.S. Treasury Securities and Obligations of U.S. Government Agency Securities, and Mortgage-Backed Securities are classified within Level 2 of the fair value hierarchy because they are not actively traded and are valued using matrix pricing and benchmarking. Matrix pricing is a mathematical technique used to value securities by relying on the securities' relationship to other benchmark quoted prices.

Foreign Exchange Contracts

Foreign exchange contract assets and liabilities are classified within Level 2 of the fair value hierarchy because there may not be an active market for each contract. However, the inputs used to calculate the value of the contract were obtained from an active market.

Convertible Debt Securities

The convertible debt valuation analysis was based on the probability-weighted expected return method ("PWERM") utilizing various scenarios for the expected payout of the instrument covering the full range of the potential outcomes.

The PWERM determines the value of an asset, based upon an analysis of future values for the subject asset, which takes into

24

Table of Contents

consideration the full range of the potential value of the subject asset. The asset value is based upon the present value of the probability of each future outcome becoming available to the asset, and the economic rights and preferences of each asset.

Stock Warrants

The warrant valuation analysis utilized the Black-Scholes model to determine the fair value of the warrant assets. When applied to a warrant, the Black-Scholes model incorporates the constant price variation of the underlying asset, the time value of money, the warrant's strike price and the time to the warrant's expiry. The fair value of the warrants was determined utilizing a five year equity volatility percentage, based on an average equity volatility derived from the comparable public companies.

The following table presents the reconciliation for all assets and liabilities measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

| | Convertible Debt Securities | Stock Warrants | Total |
|-------------------------------|-----------------------------|----------------|---------|
| Balance at September 30, 2014 | \$— | \$— | \$— |
| Additions (1) | 4,934 | 75 | 5,009 |
| Change in fair value | 273 | (5 |) 268 |
| Balance at March 31, 2015 | \$5,207 | \$70 | \$5,277 |

(1) Refer to Note 13 "Equity Method Investments".

Nonrecurring Fair Value Measurements

In addition to the assets and liabilities recorded at fair value on a recurring basis, the Company has a note receivable that is measured at fair value on a nonrecurring basis. During the third quarter of fiscal year 2014, the Company evaluated the recoverability of a loan provided to the Borrower and adjusted its value based on fair value methods. The loan is represented by a note receivable, which is classified as a Level 3 instrument, as the inputs used in the analysis are unobservable and required significant management judgment. The fair value of the loan was determined by considering the fair value of the collateral using valuation techniques, principally the discounted cash flow method, and the subordination of the Company's note to debt provided by a new lender as described in "Note 14. Note Receivable." The fair value of the loan could be different under different conditions or different assumptions, including the varying assumptions regarding future cash flows of the Borrower or discount rates.

18. Commitments and Contingencies**Capital Lease Obligation**

In March 2014, the Company exercised an option to renew the lease of a building and the related land on the Company's Chelmsford, Massachusetts campus. The Company has leased this building since 2002. By exercising this option, the Company has also contracted to purchase the building at the end of the lease period. The assets acquired under the lease were recorded at the net present value of the minimum lease payments which was then allocated to the building and the land based on their relative fair values. The cost of the building and the land under the capital lease are included in the Consolidated Balance Sheets as "Property, plant and equipment" at \$6.4 million and \$2.1 million, respectively. Depreciation expense related to the building is computed using the straight-line method over the estimated useful life of the asset. Accumulated amortization related to the lease was \$0.2 million at March 31, 2015. The obligation related to the capital lease is recorded as a short-term or long-term capital lease obligation in the Consolidated Balance Sheets depending on when payments are due. The future minimum lease payments required under the capital lease and the present value of the net minimum lease payments, as of March 31, 2015, are as follows (in thousands):

Table of Contents

| | |
|--|---------|
| Year ended September 30, | |
| 2015 | \$440 |
| 2016 | 881 |
| 2017 | 881 |
| 2018 | 6,901 |
| Total minimum lease payments | 9,103 |
| Less amounts representing interest | 1,049 |
| Total capital lease obligation | 8,054 |
| Less current portion of capital lease obligation | 881 |
| Long-term capital lease obligation | \$7,173 |

Letters of Credit

At March 31, 2015, the Company had approximately \$19.9 million of letters of credit outstanding related primarily to customer advances and other performance obligations. These arrangements guarantee the refund of advance payments received from customers in the event that the product is not delivered or warranty obligations are not fulfilled in compliance with the terms of the contract. While the Company does not anticipate that these obligations will be called, they could be called by the beneficiaries at any time before the expiration date of the particular letter of credit should the Company fail to meet certain contractual requirements.

Contingencies

The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. However, as of the date of this report, the Company believes that none of these claims will have a material adverse effect on its consolidated financial condition or results of operations. In the event of unexpected subsequent developments and given the inherent unpredictability of these legal proceedings, there can be no assurance that the Company's assessment of any claim will reflect the ultimate outcome and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company's consolidated financial condition or results of operations in particular quarterly or annual periods.

19. Subsequent Events

On April 28, 2015, the Company's Board of Directors declared a cash dividend of \$0.10 per share payable on June 26, 2015 to common stockholders of record on June 5, 2015. Dividends are declared at the discretion of the Company's Board of Directors and depend on actual cash from operations, the Company's financial condition and capital requirements and any other factors the Company's Board of Directors may consider relevant. Future dividend declarations, as well as the record and payment dates for such dividends, will be determined by the Company's Board of Directors on a quarterly basis.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

This Quarterly Report on Form 10-Q contains statements that are, or may be considered to be, forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements that are not historical facts, including statements about our beliefs or expectations, are forward-looking statements. These statements may be identified by such forward-looking terminology as "expect," "estimate," "intend," "believe," "anticipate," "may," "will," "should," "could," "continue," "likely" or similar statements or variations of such terms. Forward-looking statements include, but are not limited to, statements that relate to our future revenue, margin, costs, earnings, product development, demand, acceptance and market share, competitiveness, market opportunities and performance, levels of research and development, or R&D, the success of our marketing, sales and service efforts, outsourced activities and operating expenses, anticipated manufacturing, customer and technical requirements, the ongoing viability of the solutions that we offer and our customers' success, tax expenses, our management's plans and objectives for our current and future operations and business focus, the levels of customer spending, general economic conditions, the sufficiency of financial resources to support future operations, and capital expenditures. Such

statements are based on current expectations and involve risks, uncertainties and other factors which may cause the actual results, our performance or our achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include the Risk Factors which are set forth in our 2014 Annual Report on Form 10-K and which are incorporated herein by reference. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof

Table of Contents

and are based on information currently and reasonably known to us. We do not undertake any obligation to release the results revisions to these forward-looking statements, which may be made to reflect events or circumstances that occur after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence or effect of anticipated or unanticipated events. Precautionary statements made herein should be read as being applicable to all related forward-looking statements wherever they appear in this Quarterly Report on Form 10-Q. Any additional precautionary statements made in our 2014 Annual Report on Form 10-K should be read as being applicable to all related forward-looking statements whenever they appear in this Quarterly Report on Form 10-Q.

Overview

We are a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor manufacturing and life sciences and are a valued business partner to original equipment manufacturers, or OEMs, and equipment users throughout the world. We serve markets where equipment productivity and availability is a critical factor for our customers' success, typically in demanding temperature and/or pressure environments. Our largest served market is the semiconductor capital equipment industry. Shipments to these customers by our Brooks Product Solutions segment represented approximately 54% of our consolidated revenue for the first half of fiscal year 2015. The demand for semiconductors and semiconductor manufacturing equipment is cyclical, resulting in periodic expansions and contractions of this market. The non-semiconductor markets we serve include life sciences, industrial capital equipment and other adjacent technology markets.

We expect the semiconductor equipment market will continue to be a key end market for our products, and we continue to make investments to maintain and grow our semiconductor product and service offerings. We acquired Dynamic Micro Systems Semiconductor Equipment GmbH ("DMS") in April 2014 for \$31.6 million. DMS is a German-based provider of automated contamination control solutions for front opening unified pod, or FOUP, carriers and reticle storage, for improving yield of semiconductor processes at semiconductor fabrication plants. In October 2012, we acquired Crossing Automation, Inc. ("Crossing"), a U.S.-based provider of automation solutions and services for semiconductor front-end markets for \$59.0 million. The acquisition of these businesses provides us with the opportunity to enhance our existing capabilities with respect to manufacturing of atmospheric and vacuum solutions within the semiconductor front-end market.

We also intend to continue the development and acquisition of technologies that create opportunities outside of the semiconductor market. In October 2014, we acquired FluidX Ltd. ("FluidX"), a UK based provider of biological sample storage tubes and complementary bench-top instruments for \$15.5 million, net of cash acquired. In August 2013, we acquired certain assets and liabilities related to biological sample preparation, management and storage solutions from Matrical, Inc. ("Matrical") for \$9.3 million.

In March 2015, we entered into an agreement with Yaskawa Electric Corporation ("Yaskawa") to dissolve the Yaskawa Brooks Automation, Inc. ("YBA") joint venture, which since formed in 2006 exclusively marketed and sold Yaskawa's semiconductor and robotics products and the Company's automation hardware products to semiconductor customers in Japan. Our subsidiary in Japan purchased certain assets and liabilities of YBA for \$1.8 million, and will market and sell our automation hardware in the Japanese market going forward.

In December 2014, we entered into an agreement to purchase five-year convertible debt securities with a warrant agreement to purchase preferred units from BioCision, a privately held company, for \$2.5 million. We purchased additional securities and units in February 2015 for \$2.5 million. A portion of the funding will be used to fund a research and development program in accordance with our commercial agreement with BioCision, the remainder will be used by BioCision for general corporate purposes. As of March 31, 2015, the convertible debt securities and stock warrants were recorded at fair value for \$5.2 million and \$70,000, respectively.

In September 2014, we acquired the remaining interest in the equity of our majority owned subsidiary, Brooks Automation Asia, Ltd. ("BAA") for \$3.2 million. We have historically consolidated the financial position and results of operations from BAA and presented the portion of the income attributable to the minority shareholders in the Consolidated Statements of Operations. The acquisition of this additional interest has been accounted for as an equity transaction, and as a result, no additional assets or liabilities were recognized related to the additional interest acquired. We will no longer report a noncontrolling interest.

In March 2014, we entered into an agreement to sell the Granville-Phillips Gas Analysis & Vacuum Measurement, or Granville-Phillips, business unit to MKS Instruments, Inc. for \$87.0 million in cash. We completed the sale on May 30, 2014. We recorded a pre-tax gain of \$56.8 million and an after-tax gain of \$26.9 million. The tax charge of \$29.9 million on the gain is substantially non-cash as it is offset by our past net operating losses in the United States. Our historical financial statements have been revised to present the operating results of the Granville-Phillips business as a discontinued operation.

We report financial results in the following three segments:

• The Brooks Product Solutions segment provides a variety of products and solutions that enable improved

Table of Contents

throughput and yield in controlled operating environments. Those products include atmospheric and vacuum robots, robotic modules, and tool automation systems that provide precision handling and clean wafer environments as well as cryogenic pumps and compressors that provide vacuum pumping and thermal management solutions used to create and control critical process vacuum applications.

The Brooks Global Services segment provides an extensive range of support services, including repair services, diagnostic support services, and installation services in support of the base equipment installed by our Brooks Product Solutions segment, which enable our customers to maximize process tool uptime and productivity. This segment also provides end-user customers with spare parts and productivity enhancement upgrades to maximize customer tool productivity.

The Brooks Life Science Systems segment provides automated cold sample management systems for compound and bio sample storage, equipment for sample preparation and handling, consumables, and parts and support services to a wide range of life science customers including pharmaceutical companies, biotechnology companies, biobanks, national laboratories, research institutes and research universities.

Three and Six Months Ended March 31, 2015, Compared to Three and Six Months Ended March 31, 2014

Revenue

We reported revenue of \$139.3 million for the three months ended March 31, 2015, compared to \$125.9 million in the same prior year period, an increase of \$13.4 million or 11%. We reported revenue of \$262.0 million for the six months ended March 31, 2015, compared to \$243.0 million in the same prior year period, an increase of \$19.0 million or 8%.

Our growth was driven by our Brooks Product Solutions and Brooks Life Science Systems segments as a result of acquisitions made in the last twelve months and from organic growth in selected product lines. The change in foreign currency exchange rates, compared to the same periods in the prior year, negatively impacted our revenue by \$2.0 million and \$3.2 million for the three and six months ended March 31, 2015, respectively.

Our Brooks Product Solutions segment reported revenue of \$99.0 million for the three months ended March 31, 2015, an increase of 10% from \$89.9 million in the same prior year period. This segment reported revenue of \$181.8 million for the six months ended March 31, 2015, an increase of 6% from \$171.5 million in the same prior year period. The revenue growth was attributable to sales in our DMS business, acquired in April 2014, and from growth in certain product lines including vacuum robots and fab solution products. This growth was partially offset by a decline in vacuum systems and atmospheric robots. Revenue from DMS contributed \$9.0 million and \$16.1 million for the three and six months ended March 31, 2015, respectively. DMS sales have generated increasing revenue in each sequential quarter since the acquisition. Foreign currency exchange rates negatively impacted revenue by \$0.6 million and \$1.0 million for the three and six months ended March 31, 2015, respectively.

Our Brooks Global Services segment reported revenue of \$22.8 million for the three months ended March 31, 2015, a decrease of 2% from \$23.4 million in the same prior year period. This segment reported revenue of \$46.0 million for the six months ended March 31, 2015, a decrease of 1% from \$46.7 million in the same prior year period. The decline was primarily attributable to the impact of foreign currency exchange rates. Foreign currency exchange rates negatively impacted revenue by \$0.9 million and \$1.5 million for the three and six months ended March 31, 2015, respectively.

Our Brooks Life Science Systems segment reported revenue of \$17.5 million for the three months ended March 31, 2015, an increase of 39% from \$12.6 million in the same prior year period. This segment reported revenue of \$34.2 million for the six months ended March 31, 2015, an increase of 38%, from \$24.8 million in the same prior year period. The revenue growth was attributable to sales in our FluidX business, acquired in October 2014, and organic growth in automated sample stores. Revenue from FluidX was \$3.8 million and \$7.4 million for the three and six months ended March 31, 2015, respectively. Foreign currency exchange rates negatively impacted revenue by \$0.5 million and \$0.7 million for the three and six months ended March 31, 2015, respectively.

Gross Margin

We reported gross margins of 33.0% for the three months ended March 31, 2015, compared to 35.2% for the same prior year period. Our gross margins were 32.5% for the six months ended March 31, 2015, compared to 35.1% for

the same prior year period. The decrease in the three month results is attributable to a decline in margins in the Brooks Product Solutions segment, the Brooks Global Solutions segment and the Brooks Life Science Systems segment. The decline in the six month results is attributable to reduced margins in the Brooks Product Solutions segment and the Brooks Life Science Systems segment, partially offset by improvements in gross margins in the Brooks Global Services segment. Gross margin for the three and six months ended March 31, 2015 included \$0.0 and \$1.5 million of charges, respectively, related to the sale of inventories obtained in acquisitions to which a step-up in value was applied in our purchase accounting compared to \$0.1 million and \$0.4 million of charges for the three and six months ended March 31, 2014, respectively.

Table of Contents

Our Brooks Product Solutions segment reported gross margins of 34.4% for the three months ended March 31, 2015, as compared to 35.6% in the same prior year period and 33.5% for the six months ended March 31, 2015, as compared to 35.3% in the same prior year period. These decreases were primarily attributable to an increase in warranty costs and an unfavorable impact from product line mix. The six month period ended was also impacted by temporary operational transition costs incurred in the first quarter as we transitioned our Polycold product lines to contract manufacturing. Cost included \$0.0 and \$0.6 million of charges for the three and six months ended March 31, 2015, respectively, related to the sale of inventories obtained in acquisitions to which a step-up in value was applied in our purchase accounting. The prior period results did not include acquisition related charges.

Our Brooks Global Services segment reported gross margins of 30.8% for the three months ended March 31, 2015, as compared to 32.8% in the same prior year period. Our Brooks Global Services segment gross margins were 33.7% for the six months ended March 31, 2015, as compared to 33.2% in the same prior year period. The decrease in gross margins for the three months ended March 31, 2015 was primarily attributable to an unfavorable mix of repair services and higher consumption of materials, partially offset by improved utilization of our field service organization. The increase in gross margins for the six months ended March 31, 2015 was primarily a result of improved utilization of our field service organization.

Our Brooks Life Science Systems segment reported gross margins of 28.5% for the three months ended March 31, 2015 as compared to 37.0% in the same prior year period. Our Brooks Life Science Systems segment gross margins were 25.4% for the six months ended March 31, 2015 as compared to 37.2% in the same prior year period. The decline in margins, for the three and six month periods, was driven by the continuation of certain project cost overruns in our storage systems business which we experienced during the first quarter of fiscal year 2015 and are accounted for on a percentage of completion basis. The increase in costs was primarily due to shortfalls in our materials and resource planning process, which led to premium installation and freight costs in order to meet customer commitments. An additional contributing factor driving lower margins for the three months ended March 31, 2015 was higher excess and obsolete inventory expense incurred, some of which were incurred as part of our product line rationalization as we execute restructuring activities in the Brooks Life Science Systems segment. The three and six months ended March 31, 2015 included \$0.0 and \$1.0 million of charges, respectively, related to the sale of inventories obtained in acquisitions to which a step-up in value was applied in our purchase accounting. The three and six months ended March 31, 2014 included \$0.1 million and \$0.4 million, respectively, of step-up related charges and \$0.4 million for the impairment of the Celigo product line for the six months ended March 31, 2014.

Research and Development

Research and development expense for the three months ended March 31, 2015 was \$12.7 million, an increase of \$0.2 million compared to \$12.5 million in the same prior year period. Research and development expense for the six months ended March 31, 2015 was \$26.2 million, an increase of \$1.2 million compared to \$25.0 million in the same prior year period. Research and development expense for the three and six months ended March 31, 2015 includes \$1.6 million and \$3.0 million, respectively, of costs associated with acquisitions completed in the last twelve months.

Selling, General and Administrative

Selling, general and administrative expense was \$29.6 million for the three months ended March 31, 2015, an increase of \$1.0 million compared to \$28.6 million in the same prior year period. Selling, general and administrative expense for the six months ended March 31, 2015 was \$59.0 million, an increase of \$4.2 million compared to \$54.8 million in the same prior year period. Selling, general and administrative expense for the three and six months ended March 31, 2015 includes \$2.7 million and \$5.4 million, respectively, of costs associated with acquisitions completed in the last twelve months.

Table of Contents**Restructuring and Other Charges**

We recorded a restructuring charge of \$0.7 million for the three months ended March 31, 2015 related to severance costs. These severance costs were driven by actions taken to consolidate global functional support roles and transition the manufacturing of certain product sub-assemblies to third party contract manufacturers within the Brooks Life Science Systems segment. We incurred additional severance costs within our Brooks Product Solutions segment related to the transition of the manufacturing of certain products from our facility in Mistelgau, Germany to a third party contract manufacturer. Our manufacturing site in Germany is expected to close in 2016.

We recorded a restructuring charge of \$3.4 million for the six months ended March 31, 2015, which included \$2.2 million of severance costs and \$1.2 million of facility exit costs. Included in these restructuring charges are the severance costs described above along with \$2.7 million of restructuring costs for the three months ended December 31, 2014 as a result of actions taken to reduce our workforce in order to improve our cost structure and ongoing cost discipline. These restructuring charges related primarily to severance costs of \$1.5 million and facility exit related costs of \$1.2 million. The reduction in workforce was primarily the result of consolidation of positions in the United States and Germany, including reductions related to the integration of our acquisition of DMS. The facility exit costs were due to the on-going transition of manufacturing certain products in our line of Polycold cryochillers and compressors within the United States to a third party contract manufacturer. The facility exit costs were estimated according to future lease payments and operating costs to be paid until the termination of the lease.

We recorded a restructuring charge of \$0.8 million and \$1.5 million for the three and six months ended March 31, 2014, respectively. These costs consisted primarily of severance and other workforce-related costs and result from the consolidation of certain administrative functions in the Brooks Life Science Systems segment, the on-going transition of manufacturing certain of our Polycold products to a third party contract manufacturer and other programs designed to improve our cost structure.

Interest Income

Interest income was \$0.2 million and \$0.5 million for the three and six months ended March 31, 2015, respectively.

Interest income was \$0.3 million and \$0.5 million for the three and six months ended March 31, 2014, respectively.

Interest Expense

Interest expense related to the capital lease we entered in March 2014 was \$0.1 million and \$0.2 million for the three and six months ended March 31, 2015, respectively.

Other Income, Net

Other income, net was \$1.2 million for the three months ended March 31, 2015 as compared to \$0.1 million for the same prior year period. The increases were primarily due to \$0.7 million of currency exchange gains in our foreign subsidiaries for balances denominated in U.S. dollars and \$0.3 million of gains related to the fair value measurement of convertible debt securities. Other income, net was \$2.2 million for the six months ended March 31, 2015 as compared to \$0.3 million for the same prior year period. The increase was driven by a net gain of \$1.9 million related to currency exchange gains and losses in our foreign subsidiaries for balances primarily denominated in U.S. dollars.

Income Tax Provision (Benefit)

We recorded an income tax provision (benefit) of \$1.6 million and (\$1.6) million for the three and six months ended March 31, 2015, respectively. The tax benefit is driven by U.S. pre-tax losses in the current quarter, \$0.6 million of reductions in unrecognized tax benefits resulting from the expiration of the statute of limitations in various foreign jurisdictions and \$0.9 million of tax benefits resulting from the reinstatement of the U.S. federal research and development tax credit, retroactive to January 1, 2014. These benefits were partially offset by foreign income taxes and interest related to unrecognized tax benefits.

We recorded an income tax provision of \$1.1 million and \$1.9 million for the three and six months ended March 31, 2014, respectively. The tax provision for both periods substantially consists of U.S. and foreign income taxes, as well as interest related to unrecognized tax benefits.

Equity in Earnings (Losses) of Equity Method Investments

We recorded a loss of \$0.1 million from our equity method investments for the three months ended March 31, 2015 as compared to income of \$0.5 million for the same prior year period. We recorded a loss of \$0.6 million from our equity

method investments for the six months ended March 31, 2015 as compared to income of \$1.3 million for the same prior year period. During the first quarter of fiscal year 2015, the Company and Yaskawa agreed in principle to dissolve our joint venture. Related to this planned dissolution, YBA assessed the recoverability of assets held in the event of dissolution and communicated an

30

Table of Contents

impairment in the carrying value of the assets to its equity partners. We recorded an impairment charge of \$0.7 million for the three months ended December 31, 2014 to write down the carrying value of our equity investment in YBA to its fair value.

Income from Discontinued Operations, Net of Tax

On March 17, 2014, we entered into an agreement to sell the Granville-Phillips business unit to MKS Instruments, Inc. for \$87.0 million in cash. We determined that our Granville-Phillips business unit met the criteria to be reported as a discontinued operation. As a result, our historical financial statements have been revised to present the operating results of the Granville-Phillips business as a discontinued operation.

Reported revenue for the three months ended March 31, 2014 has been reduced by \$7.5 million. The pre-tax income from the discontinued operation was \$1.8 million for the three months ended March 31, 2014. The after-tax income from the discontinued operation was \$1.2 million for the three months ended March 31, 2014.

Reported revenue for the six months ended March 31, 2014 has been reduced by \$15.0 million. The pre-tax income from the discontinued operation was \$4.3 million for the six months ended March 31, 2014. The after-tax income from the discontinued operation was \$2.7 million for the six months ended March 31, 2014.

The tax expense allocated to the discontinued operation was \$0.7 million and \$1.6 million for the three and six months ended March 31, 2014, respectively. The allocation of tax expense to the discontinued operation represents the difference in total company tax expense when calculated with and without the results of the discontinued operation.

Net Income (Loss) Attributable to Brooks Automation, Inc.

We reported net income attributable to Brooks Automation, Inc. of \$2.7 million for the three months ended March 31, 2015, compared to \$3.2 million for the same prior year period. The decrease was primarily attributed to a decline of \$1.2 million in discontinued operations and was partially offset by an increase of \$0.6 million in continuing operations.

We reported net income (loss) attributable to Brooks Automation, Inc. of (\$23,000) for the six months ended March 31, 2015, compared to \$6.6 million for the same prior year period. The \$6.6 million decrease for the first half of the year is primarily attributable to a reduction of \$4.0 million in continuing operations and a decline of \$2.7 million in discontinued operations.

Liquidity and Capital Resources

A considerable portion of our revenue is dependent on the demand for semiconductor capital equipment. Demand for this equipment has historically experienced periodic downturns. However, we believe that we have adequate resources to fund our currently planned working capital and capital expenditure requirements for the next twelve months. The cyclical nature of our served markets and uncertainty with the current global economic environment makes it difficult for us to predict longer-term liquidity requirements with certainty. We may be unable to obtain any required additional financing on terms favorable to us, if at all. If adequate funds are not available on acceptable terms, we may be unable to successfully develop or enhance products, respond to competitive pressure or take advantage of acquisition opportunities, any of which could have a material adverse effect on our business.

At March 31, 2015, we had cash, cash equivalents and marketable securities aggregating \$207.1 million. This amount was composed of \$73.2 million of cash and cash equivalents, \$69.3 million of investments in short-term marketable securities and \$64.6 million of investments in long-term marketable securities. We have obligations under a capital lease of \$8.1 million at March 31, 2015.

Cash and cash equivalents were \$73.2 million at March 31, 2015, a decrease of \$20.9 million from September 30, 2014. The decrease in cash was primarily due to the acquisition of FluidX for \$15.5 million, net of cash acquired. Additional uses of cash include \$13.5 million of cash dividends paid to our shareholders, \$5.0 million paid to BioCision for the convertible debt securities, \$3.6 million for capital expenditures and \$1.8 million for the acquisition of certain assets and liabilities of YBA. Offsetting these payments was \$16.9 million of net sales of marketable securities and \$5.0 million of net cash provided by operating activities.

Cash provided by operating activities was \$5.0 million for the six months ended March 31, 2015, and was composed of \$18.4 million for non-cash related charges and \$13.4 million of net working capital increases. Non-cash related charges consisted of items such as \$12.7 million of depreciation and amortization, \$7.1 million of stock-based

compensation and \$0.6 million of undistributed losses of our equity method investments. These non-cash related charges were partially offset by a deferred tax benefit of \$2.7 million. The increase in working capital is primarily due to \$13.3 million in increased accounts receivables, \$6.2 million of decreases in accrued compensation and benefits, and \$3.9 million of decreased deferred revenue, partially offset by \$8.3 million of increased accounts payables, and \$4.8 million of increased accrued expenses and other current liabilities. The increase in accounts receivables is mostly due to increased shipments in our Brooks Product Solutions segment to semiconductor capital equipment customers in the third month of the three months ended March 31, 2015.

Table of Contents

Cash used in investing activities was \$9.0 million for the first half of fiscal year 2015, and includes \$15.5 million for the acquisition of FluidX, \$5.0 million paid to BioCision for the convertible debt securities, \$3.6 million of capital expenditures and \$1.8 million for the acquisition of certain assets and liabilities of YBA. These uses of cash were partially offset by \$16.9 million of net proceeds from the sale of marketable securities.

Cash used in financing activities for the six months ended March 31, 2015 was composed primarily of \$13.5 million for the quarterly cash dividends we paid to our shareholders.

In March 2014, we exercised an option to renew the lease of a building and the related land on our Chelmsford, Massachusetts campus. We have leased this building since 2002. By exercising this option, we have also contracted to purchase the building at the end of the lease period. The assets acquired under the lease were recorded at the net present value of the minimum lease payments. The cost of the building and the land under the capital lease were included in the Consolidated Balance Sheets as property, plant and equipment at \$6.4 million and \$2.1 million, respectively, and the building will be depreciated over its estimated useful life. Our remaining obligation under the capital lease is \$8.1 million, of which \$0.9 million will be paid in the next twelve months.

Except as disclosed, there have been no material changes to our contractual obligations set forth under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" in the 2014 Annual Report on Form 10-K.

We had approximately \$19.9 million of letters of credit outstanding at March 31, 2015. We issue these letters of credit related to customer advances and other performance obligations. These arrangements guarantee the refund of advance payments received from customers in the event that the product is not delivered or warranty obligations are not fulfilled in compliance with the terms of the contract. While we do not anticipate that these obligations will be called, they could be called by the beneficiaries at any time before the expiration date should we fail to meet certain contractual requirements.

On June 25, 2013, we filed a registration statement on Form S-3 with the SEC to sell up to \$200 million of securities, before any fees or expenses of the offering. Securities that may be sold include common stock, preferred stock, warrants, debt securities, depository shares, purchase contracts and purchase units. Any such offering, if it does occur, may happen in one or more transactions. The specific terms of any securities to be sold will be described in supplemental filings with the SEC. This registration statement will expire on July 1, 2016.

On April 28, 2015, our Board of Directors approved a cash dividend of \$0.10 per share of our common stock. The total dividend of approximately \$6.7 million will be paid on June 26, 2015 to shareholders of record at the close of business on June 5, 2015. Dividends are declared at the discretion of our Board of Directors and depend on actual cash from operations, our financial condition and capital requirements and any other factors our Board of Directors may consider relevant. We intend to pay quarterly cash dividends in the future; however, the amount and timing of these dividends may be impacted by the cyclical nature of certain markets that we serve. We may reduce, delay or cancel a quarterly cash dividend based on the severity of a cyclical downturn.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to a variety of market risks, including changes in interest rates affecting the return on our cash and cash equivalents, short-term and long-term investments and fluctuations in foreign currency exchange rates.

Interest Rate Exposure

Our cash equivalents consist principally of money market securities, which are short-term in nature. Our short-term and long-term investments consist mostly of highly rated corporate debt securities, U.S. Treasury securities, and obligations of U.S. Government Agencies and other municipalities. At March 31, 2015, our unrealized gain position on marketable securities was \$0.2 million, which is included in "Accumulated other comprehensive income" in the Consolidated Balance Sheets. A hypothetical 100 basis point change in interest rates would result in an annual change of approximately \$2.3 million in interest income earned.

Currency Rate Exposure

We have transactions and balances denominated in currencies other than the U.S. dollar. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. Sales in currencies other than the U.S. dollar were approximately 31% of our total sales for the first half of fiscal year 2015. These foreign sales were made primarily by our foreign subsidiaries, which have cost structures that substantially align with the currency of sale.

In the normal course of our business, we have short-term advances between our legal entities that are subject to foreign currency exposure. These short-term advances were approximately \$18.9 million at March 31, 2015, and relate to the Euro, British Pound and a variety of Asian currencies. We mitigate the impact of potential currency translation losses on these short-term intercompany advances by the timely settlement of each transaction, generally within 30 days. We also utilize forward contracts to mitigate our exposures to currency movement. We incurred a foreign currency gain of \$1.4 million for the six months ended March 31, 2015, which relates to the currency fluctuation on these advances between the time the transaction occurs and the ultimate settlement of the transaction. A hypothetical 10% change in foreign exchange rates at March 31, 2015 would result in a \$0.5 million change in our net income.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, and pursuant to Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, the Company's management, including our chief executive officer and chief financial officer, has concluded that our disclosure controls and procedures are effective.

Change in Internal Controls. There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. We cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. However, as of the date of this report, we believe that none of these claims will have a material adverse effect on our consolidated financial condition or results of operations. In the event of unexpected subsequent developments and given the inherent unpredictability of these legal proceedings, there can be no assurance that our assessment of any claim will reflect the ultimate outcome and an adverse outcome in certain matters could, from time-to-time, have a material adverse effect on our consolidated financial condition or results of operations in particular quarterly or annual periods.

Item 1A. Risk Factors

You should carefully review and consider the information regarding certain factors that could materially affect our business, consolidated financial condition or results of operations set forth under Item 1A. Risk Factors in the 2014 Annual Report on Form 10-K. There have been no material changes from the risk factors disclosed in our 2014 Annual Report on Form 10-K, although we may disclose changes to such risk factors or disclose additional factors

from time to time in our future filings with the SEC.

33

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

As part of our equity compensation program, we offer recipients of restricted stock units the opportunity to elect to sell their shares to the Company at the time of vesting to satisfy tax obligations due in connection with such vesting. The following table provides information concerning shares of our Common Stock, \$0.01 par value, purchased in connection with the forfeiture of shares to satisfy the employees' obligations with respect to withholding taxes in connection with the vesting of shares of restricted stock during the three months ended March 31, 2015. Upon purchase, these shares are immediately retired.

| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |
|-----------------------|---|---------------------------------|--|
| January 1 — 31, 2015 | 947 | \$ 13.28 | 947 |
| February 1 — 28, 2015 | 10,216 | 12.18 | 10,216 |
| March 1 — 31, 2015 | — | — | — |
| Total | 11,163 | \$ 12.27 | 11,163 |

Table of Contents

Item 6. Exhibits

The following exhibits are included herein:

| Exhibit No. | Description |
|-------------|---|
| 31.01 | Certification of the Registrant's Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.02 | Certification of the Registrant's Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32 | Certification of the Registrant's Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101 | The following material from the Company's Quarterly Report on Form 10-Q, for the quarter ended March 31, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Operations; (iii) Consolidated Statements of Comprehensive Income (Loss); (iv) the Consolidated Statements of Cash Flows; and (v) the Notes to Consolidated Financial Statements. |
| 35 | |

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BROOKS AUTOMATION, INC.

Date: April 30, 2015

/S/ Lindon G. Robertson
Lindon G. Robertson
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

Date: April 30, 2015

/S/ David Pietrantonio
David Pietrantonio
Vice President-Finance and Corporate Controller
(Principal Accounting Officer)

Table of Contents

EXHIBIT INDEX

| Exhibit No. | Description |
|-------------|---|
| 31.01 | Certification of the Registrant's Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.02 | Certification of the Registrant's Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32 | Certification of the Registrant's Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101 | The following material from the Company's Quarterly Report on Form 10-Q, for the quarter ended March 31, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Operations; (iii) Consolidated Statements of Comprehensive Income (Loss); (iv) the Consolidated Statements of Cash Flows; and (v) the Notes to Consolidated Financial Statements. |
| 37 | |